Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

International Journal of Cancer

Volumn 123, Issue 8, 2008, Pages 1848-1853

  Oei, Angèle L M ^a   Moreno, María ^b   Verheijen, René H M ^c   Sweep, Fred C G J ^a   Thomas, Chris M G ^a   Massuger, Leon F A G ^a   Von Mensdorff Pouilly, Silvia ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti MUC1 IgG antibodies; Clinical trial; Epithelial ovarian cancer; HMFG1; Survival

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MUCIN 1; MURINE MONOCLONAL ANTIBODY HMFG1; MURINE MONOCLONAL ANTIBODY HMFG1 Y 90; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOTHERAPY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CA-15-3 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; YTTRIUM RADIOISOTOPES;

EID: 51949104317     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23725     Document Type: Article

References (31)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
2. Runnebaum IB, Stickeier E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;27:73-9.
3. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL, Bodmer WF. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981;28:17-21.
4. Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG, McGuckin MA. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 1997;183:311-17.
5. Zotter S, Hageman PC, Lossnitzer A, Moot WJ, Hilgers J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988;11-12:55-101.
6. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta 1999;1455:301-13.
7. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RHM, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 2000;15:343-56.
8. Richards ER, Devine PL, Quin RJ, Fontenot DJ, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998;46:245-52.
9. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FGM, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18:574-83.
10. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003;103:97-100.
11. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000;161:589-94.
12. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006;24:571-78.
13. Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Larche M, Barkans JR, Ritter MA. Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 1988;2:894-97.
14. de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol 2004;15:1825-33.
15. Fagerberg J, Frodin JE, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive. T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after m. Ab therapy? Cancer Immunol Immunother 1993;37:264-70.
16. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm AL, Mellstedt H, Frödin JE. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 1996;42:81-7.
17. Möbus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schuhes BC, Nicomedus CF. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 2003;89:28-36.
18. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, van Kamp GJ, Kok A, Van Uffelen K, Snijdewint FGM, Paul MA, Meijer S, Hilgers J. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol 1998;19:186-95.
19. Verhoeyen ME, Saunders JA, Price MR, Marugg JD, Briggs S, Broderick EL, Eida SJ, Mooren AT, Badley RA. Construction of a reshaped HMFGl ab and comparison of its fine specificity with that of the parent mouse antibody. Immunology 1993;78:364-70.
20. Slev PR, Rawlins ML. Roberts WL. Performance characteristics of seven automated CA 15-3 assays. Am J Clin Pathol 2006;125:752-7.
21. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, Finn OJ. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125-31.
24. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:30-5.
25. Nicholson S, Bomphray CC, Thomas H, Mclndoe A, Barton D, Gore M, George AJT. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother 2004;53:809-16.
26. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, Kenemans P. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001;93:97-106.
27. Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 2007;257:47-55.
28. Courtenay-Luck N, Pegram M: Phase I study of anti-MUC1 antibody huHMFG1 (AS 1402) in patients with advanced breast cancer. Presented at the 7th Annual Meeting of the Federation of Clinical Immunology Societies, San Diego, CA, June 7-11, 2007.
29. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J. Reactivity of natural and induced human ab to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000;86:702-12.
30. Gilewski T, Adluri S, Zhang S, Ragupathi G, Houghton A, Norton L, Livingston PO. Vaccination of high risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-701.
31. Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, et al. Pilot study of a heptavalent vaccine-heyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007;13:4170-7.